2013
DOI: 10.1177/1098612x13483237
|View full text |Cite
|
Sign up to set email alerts
|

Mammary Tumours in the Cat

Abstract: This review summarises the current literature relating to aetiology, pathology, presentation, diagnosis, staging, treatment and prognosis of feline mammary tumours.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
18
0
3

Year Published

2013
2013
2022
2022

Publication Types

Select...
5
5

Relationship

0
10

Authors

Journals

citations
Cited by 46 publications
(21 citation statements)
references
References 54 publications
0
18
0
3
Order By: Relevance
“…Mammary tumours (MTs) are among the most common neoplasms in both cats and dogs, but the prevalence of malignant histological types is far higher in cats (ratio of malignant: benign is at least 4:1). Feline MTs comprise approximately 11% of feline non-integumentary neoplasms, are more commonly malignant than benign, and carry a poor prognosis attributable to a high probability of local recurrence and metastasis [1,2]. …”
Section: Introductionmentioning
confidence: 99%
“…Mammary tumours (MTs) are among the most common neoplasms in both cats and dogs, but the prevalence of malignant histological types is far higher in cats (ratio of malignant: benign is at least 4:1). Feline MTs comprise approximately 11% of feline non-integumentary neoplasms, are more commonly malignant than benign, and carry a poor prognosis attributable to a high probability of local recurrence and metastasis [1,2]. …”
Section: Introductionmentioning
confidence: 99%
“…FMCs are generally malignant hormone-independent adenocarcinomas, animals affected have a reduced survival due to early metastatic spreading 1 . The median OS in untreated cats after tumour detection varies from four months to three years depending on tumour size and clinical staging [2][3][4][5][6] . Thus, early diagnosis, prognostication, and appropriate treatment selection are of major importance.…”
mentioning
confidence: 99%
“…FMCs were staged according to the modified WHO staging system [36, 37] into: stage I, i.e., primary tumor less than 2 cm in diameter (pT1) with no evidence of regional or distant metastases (pN0-pNX and M0-MX); stage II, i.e., primary tumor 2 to 3 cm in diameter (pT2) with no evidence of regional or distant metastases (pN0-pNX and M0-MX); stage III, i.e., pT1-pT2 with evidence of regional metastases (pN+), or primary tumor greater than 3 cm in diameter (pT3), any pN but without evidence of distant metastases (M0-MX); and stage IV, i.e., evidence of distant metastases (M1) regardless of tumor size or nodal stage.…”
Section: Methodsmentioning
confidence: 99%